U.S., June 25 -- ClinicalTrials.gov registry received information related to the study (NCT07033494) titled 'A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)' on June 13.
Brief Summary: Researchers want to know if the study treatment called MK-2214 works to slow certain changes in the brains of people with Alzheimer's disease (AD). AD is a type of dementia that can cause loss of memory, communication (such as speech), and decision-making skills. It can limit a person's ability to do daily tasks. MK-2214 is a study treatment designed to slow down AD.
The goals of the study are to learn:
* If MK-2214 slows the spread of tau in the brain compared to placebo. Tau is a protein that accumulates in AD & damages...